Interdisciplinary Consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence–Based Medicine (EBM)

Chairmanship: H.–J. Schmoll (Halle), S. Krege (Essen), R. Souchon (Hagen) Members of the Consensus Conference: AIO (Medical Oncology Working Party): PD Dr. J. Beyer (Marburg), Prof. C. Bokemeyer (Tübingen), Prof. C. Clemm* (Bad Trissl), PD Dr. H.–G. Derigs* (Mainz), PD Dr. A. Gerl (Munich), PD Dr. A. Harstrick (Darmstadt), Prof. H.–J. Schmoll (Halle), Prof. W. Siegert (Berlin), Dr. M. de Wit (Mrs.)* (Hamburg) AUO (Urooncology Working Party): PD Dr. P. Albers (Bonn), Prof. K.–P. Dieckmann (Hamburg), Dr. M. Hartmann (Hamburg), PD Dr. A. Heidenreich (Marburg), Dr. S. Kliesch (Mrs.) (Münster), PD Dr. K.U. Koehrmann (Mannheim), Dr. S. Krege (Mrs.) (Essen), PD Dr. M. Kuczyk (Hannover), Prof. P. Walz (Lüdenscheid), Dr. S. Weinknecht (Berlin), Prof. L. Weissbach (Berlin), Dr. E. Winter (Mrs.) (Schwerin), Prof. W. Hoeltl (Vienna) ARO (Radiooncology Working Party): Prof. M. Bamberg (Tübingen), Dr. J. Classen* (Tübingen), Prof. R.P. Mueller* (Cologne), PD Dr. H. Schmidberger (Göttingen), Dr. R. Souchon (Hagen) Additional participants: Prof. V. Loy* (Berlin), Prof. C. Wittekind* (Leipzig) *Cooperating members

[1]  L. Strauss.  Einsatz der Positronen-Emissions-Tomographie in der Onkologie , 2008 .

[2]  S. Rodenhuis,et al.  Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP , 1999, International journal of cancer.

[3]  C. Stief,et al.  Management of the post‐chemotherapy residual mass in patients with advanced stage non‐seminomatous germ cell tumors (nsgct) , 1999, International journal of cancer.

[4]  Craig R. Nichols.  Treatment of recurrent germ cell tumors. , 1999, Seminars in surgical oncology.

[5]  L. Weissbach,et al.  Prognostic Factors in Seminomas with Special Respect to HCG: Results of a Prospective Multicenter Study , 1999, European Urology.

[6]  C. Meisner,et al.  First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Günther,et al.  Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. , 1999, Urology.

[8]  P. Bossuyt,et al.  Empirical evidence of design-related bias in studies of diagnostic tests. , 1999, JAMA.

[9]  S. Fosså,et al.  Health-related quality of life in patients treated for testicular cancer. , 1999, Current opinion in urology.

[10]  M. Dietlein,et al.  [The lymph node staging of malignant testicular germ-cell tumors]. , 1999, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[11]  Norbert Avril,et al.  Relevance of Positron Emission Tomography (PET) in Oncology , 1999, Strahlentherapie und Onkologie.

[12]  S. Fosså,et al.  Postchemotherapy Residual Masses in Germ Cell Tumor Patients. Content, Clinical Features, and Prognosis , 1999 .

[13]  L. Collette,et al.  Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. , 1999, Journal of the National Cancer Institute.

[14]  C. Bokemeyer,et al.  Long-term effects on sexual function and fertility after treatment of testicular cancer , 1999, British Journal of Cancer.

[15]  A. Horwich,et al.  Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Howard,et al.  Imaging of the thorax in the management of germ cell testicular tumours. , 1999, Clinical radiology.

[17]  D. Böhlen,et al.  Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. , 1999, The Journal of urology.

[18]  P. Albers,et al.  Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. , 1999, Urology.

[19]  S. Fosså,et al.  Treatment outcome of patients with brain metastases from malignant germ cell tumors , 1999, Cancer.

[20]  C. Catton,et al.  Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. , 1999, The Journal of urology.

[21]  N. Shahab.  Management of germ cell tumours of the testis , 1999, The Lancet.

[22]  D. Dearnaley,et al.  Markers and management of germ-cell tumours of the testes , 1998, The Lancet.

[23]  L. Collette,et al.  Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. , 1998, British Journal of Cancer.

[24]  A. Nicholson,et al.  Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Fosså,et al.  Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. , 1998, The Journal of urology.

[26]  R. Oyen,et al.  [Primary retroperitoneal extragonadal germ cell tumor]. , 1998, Journal belge de radiologie.

[27]  L. Einhorn,et al.  Urological Survey: Abstracts: Diagnostic Urology and Testis CancerPostchemotherapy Retroperitoneal Lymph Node Dissection is Effective Therapy in Selected Patients With Elevated Tumor Markers After Primary Chemotherapy Alone , 1998 .

[28]  G. Bauman,et al.  Postoperative radiotherapy for Stage I/II seminoma: results for 212 patients. , 1998, International journal of radiation oncology, biology, physics.

[29]  L. Collette,et al.  Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. , 1998, British Journal of Cancer.

[30]  J. Høie,et al.  Treatment and outcome of patients with extragonadal germ cell tumours--the Norwegian Radium Hospital's experience 1979-94. , 1998, British Journal of Cancer.

[31]  P. Warde,et al.  Surveillance for stage I testicular seminoma. Is it a good option? , 1998, The Urologic clinics of North America.

[32]  J. Donohue,et al.  Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? , 1998, The Urologic clinics of North America.

[33]  B. Lowe,et al.  A rational approach to managing stage I nonseminomatous germ cell cancer. , 1998, The Urologic clinics of North America.

[34]  L. Einhorn,et al.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Bokemeyer,et al.  Salvagetherapie rezidivierter und refraktärer Hodentumoren , 1998, Der Onkologe.

[36]  J. Ong,et al.  Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumours. , 1998, British journal of urology.

[37]  D. Ondruš,et al.  Prognostic Factors in Clinical Stage I Nonseminomatous GermCell Testicular Tumors: Rationale for Different Risk-Adapted Treatment , 1998, European Urology.

[38]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.

[39]  H. von der Maase,et al.  Effect of chemotherapy on carcinoma in situ of the testis. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  C. Meisner,et al.  Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. , 1998, International journal of radiation oncology, biology, physics.

[41]  L. Einhorn,et al.  Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Catalano,et al.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. Molenaar,et al.  Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors , 1998 .

[44]  Jewett Ma,et al.  Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998 .

[45]  H. Thaler,et al.  Clinical stage I testis cancer: long-term outcome of patients on surveillance. , 1998, The Journal of urology.

[46]  R. Paterson,et al.  Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? , 1998, British journal of urology.

[47]  R Sylvester,et al.  Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  L. Collette,et al.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Belldegrun,et al.  Positron emission tomography in urological oncology. , 1998, The Journal of urology.

[50]  N. Skakkebæk,et al.  Gonadal function in men with testicular cancer: Biological and clinical aspects , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[51]  L. Hertle,et al.  Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies. , 1997, Human reproduction.

[52]  H. Herr,et al.  Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? , 1997, British journal of urology.

[53]  B. Kohler,et al.  Risk of second malignant neoplasms among long-term survivors of testicular cancer. , 1997, Journal of the National Cancer Institute.

[54]  J. Grygiel,et al.  Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: late relapse may occur. , 1997, Urology.

[55]  C. Meisner,et al.  Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: A prospective multicenter study , 1997 .

[56]  B. Stoffel‐Wagner,et al.  Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. , 1997, The Journal of urology.

[57]  C. Bokemeyer,et al.  Germ cell tumor (GCT): Staging and therapy control with 18FDG-PET. First results of German multicenter trial , 1997 .

[58]  F. Mostofi,et al.  Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. , 1997, The Journal of urology.

[59]  P. Albers.  Diagnostik und Therapie von Hodentumoren , 1997, Der Urologe A.

[60]  R. Motzer,et al.  High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Pont,et al.  Fertility after chemotherapy for testicular germ cell cancer. , 1997, Fertility and sterility.

[62]  O. Dahl,et al.  Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. , 1997, European journal of cancer.

[63]  C. Bokemeyer,et al.  Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. , 1997, European journal of cancer.

[64]  L. Collette,et al.  Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Horwich,et al.  Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. , 1997, European journal of cancer.

[66]  S. Fosså,et al.  Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  C. Catton,et al.  Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. , 1997, The Journal of urology.

[68]  R. Sagerman,et al.  Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma. , 1997, American journal of clinical oncology.

[69]  L. Einhorn,et al.  Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  C. Bokemeyer,et al.  Treatment of brain metastases in patients with testicular cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  S. Culine,et al.  Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. , 1997, British journal of urology.

[72]  J. Best,et al.  The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. , 1997, Clinical radiology.

[73]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[74]  U. Engelmann,et al.  Testis-preserving surgery in bilateral testicular germ cell tumours. , 1997, British journal of urology.

[75]  K. Dieckmann,et al.  Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  A. Horwich,et al.  An analysis of surveillance for stage I combined teratoma--seminoma of the testis. , 1996, British Journal of Cancer.

[77]  J. Olsen,et al.  Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population‐based study , 1996, International journal of cancer.

[78]  I. Kiricuta,et al.  Omission of the pelvic irradiation in stage I testicular seminoma: a study of postorchiectomy paraaortic radiotherapy. , 1996, International journal of radiation oncology, biology, physics.

[79]  M. Williams,et al.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  V. Budach,et al.  Results of radiotherapy for 230 patients with stage I-II seminomas. , 1996, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[81]  J. Donohue,et al.  Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. , 1996, The Journal of urology.

[82]  J. Pont,et al.  Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  M. Mazumdar,et al.  Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  M. Jewett,et al.  What is the appropriate follow-up after treatment? , 1996, Seminars in urologic oncology.

[85]  P. Albers,et al.  Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. , 1996, The Journal of urology.

[86]  K. Kopecky,et al.  Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. , 1995, The Journal of urology.

[87]  J. Thornhill,et al.  Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. , 1995, European journal of cancer.

[88]  P. Goodman,et al.  Stage I testicular seminoma: results of adjuvant irradiation and surveillance. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Donohue,et al.  The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer. , 1995, The Journal of urology.

[90]  N. Nicolai,et al.  A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. , 1995, The Journal of urology.

[91]  T. Krahe,et al.  Quantifizierung der Lymphknotenperfusion mittels farbkodierter Duplexsonographie , 1995 .

[92]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  H. D. de Bruijn,et al.  Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  G. Kerr,et al.  Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. , 1995, The British journal of radiology.

[95]  Peter Clark,et al.  Original Articles: Testis Cancer: A Review of Scrotal Violation in Testicular Cancer: Is Adjuvant Local Therapy Necessary? , 1995 .

[96]  J. Baniel,et al.  Complications of post-chemotherapy retroperitoneal lymph node dissection. , 1995, The Journal of urology.

[97]  J. Moul,et al.  Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. , 1994, Urology.

[98]  P. Albers,et al.  Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors , 1994, Cancer.

[99]  J. Donohue,et al.  Complications of primary retroperitoneal lymph node dissection. , 1994, The Journal of urology.

[100]  R. Motzer,et al.  Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy , 1994, Cancer.

[101]  H. Ozen,et al.  Postchemotherapeutic surgery for metastatic testicular germ cell tumors: results of extended primary chemotherapy and limited surgery. , 1994, Urology.

[102]  B. Kennedy,et al.  Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis , 1994, Cancer.

[103]  C. Perez,et al.  Radiation therapy for stage I and IIA testicular seminoma. , 1994, International journal of radiation oncology, biology, physics.

[104]  J. Moul,et al.  Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. , 1994, Cancer research.

[105]  C. Bokemeyer,et al.  Secondary neoplasms following treatment of malignant germ cell tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  W. See,et al.  Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. , 1993, The Journal of urology.

[107]  N. Jørgensen,et al.  Immunohistochemical expression of embryonal marker TRA‐1–60 in carcinoma in situ and germ cell tumors of the testis , 1993, Cancer.

[108]  A. Karjalainen,et al.  Case-control study of congenital anomalies in children of cancer patients. , 1993, BMJ.

[109]  G. Zagars,et al.  Post-orchiectomy radiotherapy for stages I and II testicular seminoma. , 1993, International journal of radiation oncology, biology, physics.

[110]  K. Dieckmann,et al.  Paternity in a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia. , 1993, International journal of andrology.

[111]  F. Debruyne,et al.  Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. , 1993, British journal of urology.

[112]  N. Skakkebaek,et al.  Semen quality in testicular tumour and CIS in the contralateral testis , 1993, The Lancet.

[113]  D. Dearnaley,et al.  Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. , 1993, British journal of urology.

[114]  J. Thornhill,et al.  Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. , 1993, The Journal of urology.

[115]  L. Einhorn,et al.  Surgical salvage of chemorefractory germ cell tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  R. Motzer,et al.  Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. , 1992, The Journal of urology.

[117]  G. Haas,et al.  Accuracy of frozen section examination of testicular tumors. , 1992, Urology.

[118]  A. Horwich,et al.  Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  W. van Putten,et al.  Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[120]  H. Tongaonkar,et al.  Value of retroperitoneal lymph node dissection in advanced testicular seminoma , 1992, Journal of surgical oncology.

[121]  N. Nicolai,et al.  Comparison between clinical and pathological staging in low stage non-seminomatous germ cell testicular tumors , 1992, The Journal of urology.

[122]  L. Weissbach,et al.  Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. , 1991, The Journal of urology.

[123]  A. Pawinski,et al.  Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis. , 1991, Clinical oncology (Royal College of Radiologists (Great Britain)).

[124]  A. Giwercman,et al.  Placental‐like alkaline phosphatase as a marker of carcinoma‐in‐situ of the testis. Comparison with monoclonal antibodies M2A and 43–9F , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[125]  J. Ellis,et al.  Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. , 1991, The Journal of urology.

[126]  N. Geller,et al.  Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  J. Donohue,et al.  Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. , 1990, The Journal of urology.

[128]  P. Kellokumpu-Lehtinen,et al.  Results of treatment in irradiated testicular seminoma patients. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[129]  R. Grundy,et al.  Long-term toxicity of chemotherapy for testicular cancer--the cost of cure. , 1990, British Journal of Cancer.

[130]  S. Kaasa,et al.  Long-term somatic side-effects and morbidity in testicular cancer patients. , 1990, British Journal of Cancer.

[131]  S. Fosså,et al.  Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. , 1989, The Journal of urology.

[132]  J. Richie,et al.  Radiation therapy of seminoma: 17-year experience at the Joint Center for Radiation Therapy. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[133]  C. Wittekind,et al.  TNM Klassifikation maligner Tumoren , 1987 .

[134]  D. Stablein,et al.  Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. , 1987, The New England journal of medicine.

[135]  J. Richie,et al.  Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. , 1987, AJR. American journal of roentgenology.

[136]  L. Einhorn,et al.  Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  R. Motzer,et al.  Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  O. Kaalhus,et al.  The treatment of advanced metastatic seminoma: experience in 55 cases. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  G. Bosl,et al.  Residual mass after chemotherapy for seminoma: changing concepts of management. , 1987, The Journal of urology.

[140]  K. Kopecky,et al.  Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. , 1987, The Journal of urology.

[141]  R. Babaian,et al.  The role of radiation in stage II testicular seminoma. , 1987, International journal of radiation oncology, biology, physics.

[142]  W. Hendry,et al.  The significance of scrotal interference in stage I testicular cancer managed by orchiectomy and surveillance. , 1986, British journal of urology.

[143]  K. O'Connell,et al.  Predictors of recurrent clinical stage I nonseminomatous testicular cancer. A prospective clinicopathologic study. , 1986, Urology.

[144]  G. Bosl,et al.  Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors , 1986, Cancer.

[145]  W. Hendry,et al.  Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. , 1985, British journal of urology.

[146]  C. Logothetis,et al.  Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. , 1985, The Journal of urology.

[147]  A. Horwich,et al.  Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). , 1985, British Journal of Cancer.

[148]  S. Monfardini,et al.  No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. , 1984, The Journal of urology.

[149]  J. Herman,et al.  Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. , 1982, International journal of radiation oncology, biology, physics.

[150]  A. Tubaro.  RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumours? Results of a prospective multicenter trial including quality of life assessment. , 2001 .

[151]  L. Einhorn,et al.  Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  U. Pichlmeier,et al.  Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? , 2000, Urology.

[153]  W. Siegert,et al.  High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis , 1999 .

[154]  P. White,et al.  Testicular cancer--who needs surveillance pelvic CT? , 1999, Clinical radiology.

[155]  C. Catton,et al.  Management of stage II seminoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  R. Coleman,et al.  The management and clinical course of testicular seminoma: 15 years' experience at a single institution. , 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

[157]  M. Hartmann,et al.  BEI WELCHEN MARKERPOSITIVEN PATIENTEN MIT KEIMZELL-TUMOREN IST DIE RESIDUAL-TUMORRESEKTION SINNVOLL? , 1998 .

[158]  P. Albers,et al.  Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  Christopher U. Jones,et al.  Is pelvic RT necessary in the treatment of stage I testicular seminoma , 1998 .

[160]  I. Sesterhenn,et al.  Histological Typing of Testis Tumours , 1998, World Health Organization.

[161]  P. Albers,et al.  HODENTUMOREN: TODESFALLE UND REZIDIVE NACH INADAQUATER THERAPIE , 1998 .

[162]  W. Wilmanns,et al.  Late relapse of germ cell tumors after cisplatin-based chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[163]  G. Morgan,et al.  Management of seminoma of the testis: recommendations based on treatment results. , 1997, The Australian and New Zealand journal of surgery.

[164]  L. Weissbach,et al.  Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminoma patients. An analysis of various parameters. , 1997, European urology.

[165]  U. Engelmann,et al.  Paternity in patients with bilateral testicular germ cell tumors. , 1997, European urology.

[166]  M. Goepel,et al.  Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. , 1997, European urology.

[167]  M. Mason,et al.  Treatment of stage I seminoma: more choices, more dilemmas. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[168]  H. Schmoll.  Maligne Keimzelltumoren des Mannes , 1997 .

[169]  S. Reske,et al.  Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz , 1996, Nuklearmedizin.

[170]  M. Cullen,et al.  Alpha-foetoprotein heterogeneity: what is its value in managing patients with germ cell tumours? , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[171]  E. Nieschlag,et al.  Cryopreservation of semen from adolescent patients with malignancies. , 1996, Medical and pediatric oncology.

[172]  R. Motzer.  Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: what is its role? , 1996, Seminars in urologic oncology.

[173]  J. Richie,et al.  The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). , 1995, The Journal of urology.

[174]  L. Weissbach,et al.  Organ preserving surgery of malignant germ cell tumors. , 1995, The Journal of urology.

[175]  J. Richie,et al.  A conservative approach to bilateral testicular germ cell tumors. , 1995, The Journal of urology.

[176]  T. Ahlering,et al.  Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. , 1994, Urology.

[177]  D. Dearnaley,et al.  Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. , 1994, The Journal of urology.

[178]  W. Wilmanns,et al.  Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. , 1993, European journal of cancer.

[179]  M. Ro̸rth,et al.  Surveillance following orchidectomy for stage I seminoma of the testis. , 1993, European journal of cancer.

[180]  P. Goodman,et al.  Results of a policy of surveillance in stage I testicular seminoma. , 1993, International journal of radiation oncology, biology, physics.

[181]  F. Mostofi,et al.  Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  H. Kienzer,et al.  Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  J. Richie.  The surgical management of advanced abdominal disease. , 1984, Seminars in urology.

[184]  A. Barrett,et al.  The role of surgery in the combined management of metastases from malignant teratomas of testis. , 1980, British journal of urology.